Trial Profile
A Phase 1b Open-label Study to Evaluate the Safety and Efficacy of CC-122 in Combination With Obinutuzumab (GA101) in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Indolent Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 25 Oct 2023
Price :
$35
*
At a glance
- Drugs Avadomide (Primary) ; Obinutuzumab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 19 Oct 2023 Status changed from active, no longer recruiting to completed.
- 08 Aug 2023 Planned End Date changed from 20 Feb 2023 to 31 Aug 2023.
- 08 Aug 2023 Planned primary completion date changed from 20 Feb 2023 to 31 Aug 2023.